Canaccord Genuity Group Cuts Health Catalyst (NASDAQ:HCAT) Price Target to $10.00

Health Catalyst (NASDAQ:HCAT) had its price target decreased by Canaccord Genuity Group from $11.00 to $10.00 in a research report report published on Tuesday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Several other analysts also recently weighed in on HCAT. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research note on Wednesday, January 8th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Citigroup reduced their price objective on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, January 10th. Royal Bank of Canada lowered their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 15th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 price target (up from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Health Catalyst presently has an average rating of “Moderate Buy” and an average target price of $10.91.

Health Catalyst Stock Up 3.2 %

Health Catalyst stock opened at $5.79 on Tuesday. The firm has a market capitalization of $352.32 million, a P/E ratio of -4.29 and a beta of 1.36. The company has a 50-day simple moving average of $7.39 and a 200-day simple moving average of $7.51. Health Catalyst has a one year low of $5.35 and a one year high of $10.99. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.22) EPS. As a group, equities analysts expect that Health Catalyst will post -0.33 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $7.51, for a total value of $39,119.59. Following the completion of the transaction, the chief operating officer now owns 91,253 shares in the company, valued at $685,310.03. This trade represents a 5.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Linda Llewelyn sold 6,442 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total value of $37,363.60. Following the sale, the insider now owns 92,260 shares in the company, valued at approximately $535,108. The trade was a 6.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,169 shares of company stock worth $639,174 in the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Health Catalyst

Several large investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC grew its holdings in shares of Health Catalyst by 438.5% during the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after buying an additional 3,221,408 shares in the last quarter. Impax Asset Management Group plc boosted its position in Health Catalyst by 16.4% during the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after acquiring an additional 360,201 shares during the period. Millennium Management LLC grew its stake in Health Catalyst by 96.3% during the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after acquiring an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of Health Catalyst by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after purchasing an additional 25,000 shares during the period. Finally, Daventry Group LP lifted its position in shares of Health Catalyst by 3.9% in the second quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after purchasing an additional 84,178 shares in the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.